Preparation method and application of secondary metabolites of Raffaelea lauricola
By isolating and purifying A'-Neogammacer-21-en-15α-ol on the Raffaelea lauricola strain, it solved its problem not found in Raffaelea lauricola, demonstrating its inhibitory effect on the human breast cancer cell line MCF-7, The preparation of high-purity compounds and their potential applications in the pharmaceutical field have been achieved.
Patent Information
- Application Number
- CN202211087400.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-07
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2042-09-07
AI Technical Summary
The isolation of A'-Neogammacer-21-en-15α-ol in Raffaelea lauricola and its inhibitory effect on human breast cancer cell line MCF-7 have not been found, limiting its potential application in the medical field.
The preparation of secondary metabolites was carried out on the Raffaelea lauricola strain, and A'-Neogammacer-21-en-15α-ol was isolated and purified by continuous culture, drying, ultrasonic extraction, reverse phase silica gel column chromatography, and passed through MTT Its inhibitory effect on MCF-7 cells was determined.
The high-purity A'-Neogammacer-21-en-15α-ol was successfully isolated and identified, and its 50% inhibition rate on human breast cancer cell line MCF-7 was demonstrated, showing its inhibitory effect on cancer cell growth Potential application value.
Smart Images

Figure CN115323028B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of separating active substances from bacterial strains, and specifically relates to Raffaelea lauricola Secondary metabolites (hopane-type triterpenoids A'-Neogammacer-21-en-15 α -ol) and its new use in inhibiting human breast cancer cell line MCF-7. Background Art
[0002] Raffaelea lauricola It is a fungus-eating beetle ( Ambrosia beetle ) is a highly pathogenic companion fungus that causes tree wilt disease. Scholars have long been committed to studying its pathogenic mechanism. With the continuous deepening of research, some active substances such as plant growth inhibition and antibacterial have been obtained from other species of this genus. This indicates that this fungus has great potential application value in biological pesticides or medicines.
[0003] A'-Neogammacer-21-en-15 α -ol is a hopane triterpenoid, and hopane triterpenoids have anti-tumor, anti-inflammatory, and antibacterial activities. α -ol's chemical structure to generate various new active substances. So far, no new active substances have been found in Raffaelea lauricola A'-Neogammacer-21-en-15 α -ol's report. Summary of the invention
[0004] The object of the present invention is to provide a Raffaelea lauricola Secondary metabolites and new uses thereof for inhibiting human breast cancer cell line MCF-7, wherein the metabolites are: hopane-type triterpenoid compound A'-Neogammacer-21-en-15 α -ol.
[0005] Said Raffaelea lauricola The preparation method of secondary metabolites adopts the following technical scheme:
[0006] 1) Raffaelea lauricola After activation, the bacterial block is inoculated into PDB medium, and cultured continuously at 140-180 r / min and 20-28° C. for 5-10 days. The culture is transferred to a modified rice medium at an inoculum amount of 15wt%-20wt%, and cultured statically at 20-28° C. for 28-40 days to obtain mycelium.
[0007] 2) The mycelium obtained in step 1) is dried at room temperature, then ground and pulverized, soaked in 1-2 times the volume of ethyl acetate for 12-24 hours, ultrasonicated for 40-60 minutes, and the extract is collected. 1-2 times the volume of ethyl acetate of the mycelium is added to the residue, ultrasonicated for 40-60 minutes, and the extract is collected. The above steps are repeated to obtain three extracts, combined and concentrated to obtain a crude extract.
[0008] 3) Dissolve the extract in chloroform or dichloromethane, and then 18 The sample was mixed, dry loaded on the column, and gradient eluted with a methanol: water volume ratio of 1:9-9:1. The eluate with a methanol: water volume ratio of 9:1 was collected and concentrated by rotary evaporation to obtain component A.
[0009] 4) Dissolve component A with 1 volume of chloroform, pass through a 200-300 mesh silica gel column, start gradient elution with a volume ratio of petroleum ether: ethyl acetate of 30:1, collect part of the eluate with a volume ratio of petroleum ether: ethyl acetate of 10:1, and concentrate by rotary evaporation to obtain an extract, pass through a 200-300 mesh silica gel column again, start gradient elution with a volume ratio of petroleum ether: chloroform of 8:1, collect part of the eluate with a volume ratio of petroleum ether: chloroform of 4:1, pass through a 200-300 mesh silica gel column chromatography again, start gradient elution with a volume ratio of petroleum ether: ethyl acetate of 20:1, collect part of the eluate with a volume ratio of petroleum ether: ethyl acetate of 5:1, and rotary evaporation to obtain a white powder A'-Neogammacer-21-en-15α-ol, whose structural formula is shown below:
[0010] .
[0011] Furthermore, the composition of the improved rice culture medium in step 1) is: 100 g rice, 10 g sawdust, 120 mL pure water, and high pressure sterilization at 121° C. for 20 min.
[0012] Furthermore, in step 1), the size of the inoculated bacterial block is 0.5×0.5 cm, and the inoculation amount is 4 blocks.
[0013] Furthermore, in step 2), the power of ultrasound is 400 W and the frequency is 35 KHz.
[0014] Furthermore, the reverse phase silica gel C used in step 3) 18 Particle size 40-60 μm, pore size 120 Å.
[0015] Furthermore, in the step 4), the volume ratio of petroleum ether:ethyl acetate in the gradient elution is 30:1, 20:1, 10:1, 7:1, 5:1; the volume ratio of petroleum ether:chloroform is 8:1, 6:1, 4:1.
[0016] The present invention has the following significant advantages: the separation and purification is simple, the cost is low, and the operation is easy; the prepared compound has high purity and good repeatability. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 A'-Neogammacer-21-en-15 α -ol 1 H NMR spectrum (CDCl 3 );
[0018] Figure 2 A'-Neogammacer-21-en-15 α -ol 13 C NMR spectrum (CDCl 3 );
[0019] Figure 3 A'-Neogammacer-21-en-15 α DEPT135 spectrum of -ol (CDCl 3 );
[0020] Figure 4 A'-Neogammacer-21-en-15 α COSY spectrum of -ol (CDCl 3 );
[0021] Figure 5 A'-Neogammacer-21-en-15 α -olHMBC spectrum (CDCl 3 );
[0022] Figure 6 A'-Neogammacer-21-en-15 α HSQC spectrum of -ol (CDCl 3 ). DETAILED DESCRIPTION
[0023] In order to make the above features and advantages of the present invention more clearly understood, the following embodiments are given for detailed description. The methods of the present invention are all conventional methods in the art unless otherwise specified.
[0024] The present invention uses Raffaelea lauricola The strain number is Hulcr7161.
[0025] Example 1 Isolation of Active Secondary Metabolite A'-Neogammacer-21-en-15α-ol
[0026] 1) Take Raffaelea lauricola(strain preserved in this laboratory) was used as the material. Four bacterial blocks of 0.5×0.5 cm in size were picked out under sterile conditions and inoculated into PDB medium (3.9 g potato glucose powder, 100 ml pure water, filled into a 250 mL conical flask, sterilized at 121°C under high pressure for 20 min), and cultured continuously at 160 r / min and 25°C for 7 days as the primary culture. The inoculum was transferred to a modified rice medium (100 g rice, 10 g sawdust, added into 120 mL pure water, sterilized at 121°C under high pressure for 20 min) at a 10wt% inoculum amount, and continued to be statically cultured at 25°C for 35 days as the secondary culture.
[0027] 2) Collect the mycelium cultured for 35 days, dry it at room temperature, grind it into powder, add 1 volume of ethyl acetate to soak it for 12 hours, sonicate it for 40 minutes, filter to obtain the extract, add 1 volume of ethyl acetate of the mycelium to the residue, sonicate it for 40 minutes, collect the extract, repeat the above steps again, and obtain three extracts, combine them, concentrate them and evaporate them to obtain the crude extract.
[0028] 3) The extract was dissolved in chloroform and the sample was analyzed using a reverse phase C 18 The sample was mixed with silica gel and loaded onto the column by dry method. The product was eluted with a gradient of methanol: water starting from a volume ratio of 1:9 (the volume ratio of methanol: water was 1:9, 2:8, 3:7, 4:6, 6:4, 7:3, 8:2, 9:1). The portion with a volume ratio of methanol: water of 9:1 was collected and rotary evaporated to obtain the crude product.
[0029] 4) Dissolve the crude product with 1 volume of chloroform, apply to a 200-300 mesh silica gel column, and start gradient elution with a volume ratio of petroleum ether: ethyl acetate of 30:1 (gradient elution ratio is 30:1, 20:1, 10:1), collect the eluate with a volume ratio of petroleum ether: ethyl acetate of 10:1, and concentrate by rotary evaporation to obtain an extract, and then pass through a 200-300 mesh silica gel column, and start gradient elution with a volume ratio of petroleum ether: chloroform of 8:1 (gradient elution ratio is 8:1, 6:1, 4:1), collect the eluate with a volume ratio of petroleum ether: chloroform of 4:1, and then pass through a 200-300 mesh silica gel column for chromatography, and start gradient elution with a volume ratio of petroleum ether: ethyl acetate of 20:1 (gradient elution ratio is 20:1, 10:1, 8:1, 5:1), the eluate with a volume ratio of petroleum ether to ethyl acetate of 5:1 was collected and rotary evaporated to obtain a white powdery hopane-type triterpenoid compound A'-Neogammacer-21-en-15α-ol.
[0030] The extraction rate was calculated to be 1.320% (extraction rate % = weight / total amount of mycelium extract × 100%).
[0031] Example 2 Inhibitory effect of A'-Neogammacer-21-en-15α-ol on human breast cancer cell line MCF-7
[0032] 1) The antitumor activity of the compounds was determined by the MTT method. MCF-7 cells were cultured in RPMI1640 medium in a saturated humidity incubator at 37°C and 5% CO 2 Both of the above culture media were supplemented with 10% fetal bovine serum and penicillin (1×10 5 IU / L) and streptomycin (100 mg / L) and can be used for experiments after being cultured to the logarithmic growth phase.
[0033] 2) In a 96-well plate, 180 μL per well contains 5×10 3 cells, set the concentration of the test compound (200, 100, 50, 25, 12.5, 6.25 μM) according to the two-fold dilution method and dilute with DMSO, the positive control is cisplatin, and the negative control is DMSO solution, cultured in a 37°C incubator for 48 h, added 20 μL of MTT solution to each well, and cultured for another 4 h, then aspirated the liquid in the well, added DMSO and shaken to fully dissolve the formazan, and measured the absorbance (A) at a wavelength of 570 nm.
[0034] 3) Calculate the cell growth inhibition rate according to the formula:
[0035] Inhibition rate (%) = [(A control - A experiment) / (A control - A blank)] × 100%. The results are shown in Table 1.
[0036] Table 1 Inhibitory activity of target active substances on human breast cancer cells
[0037]
[0038] The IC of the target active compound was calculated by GraphPad Prism 8 software. 50 =55.38 μg / mL, IC 50 That is, the drug concentration at which the inhibition rate reaches 50%, indicating that the active metabolite A'-Neogammacer-21-en-15 α When the -ol concentration reached 55.38 μg / mL, the growth inhibition rate of human breast cancer cell line was 50%.
[0039] The above-described embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Equivalent substitutions or changes made by those skilled in the art based on the present invention are within the protection scope of the present invention. The protection scope of the present invention shall be subject to the claims.
Claims
1. Raffaelea lauricola Method for preparing secondary metabolites, Features: The following steps are involved: 1) Raffaelea lauricola After activation, the bacterial block was inoculated into PDB medium, and cultured continuously for 5-10 days at 160-180 r / min and 20-28°C, and then transferred to rice medium at an inoculum of 15wt%-20wt%, and continued to be statically cultured at 20-28°C for 28-40 days to obtain mycelium; 2) Dry the mycelium obtained in step 1) at 35-40° C. and grind it into powder, soak it in 1-2 times the volume of ethyl acetate for 12-24 hours, sonicate it for 40-60 minutes, collect the extract, add 1-2 times the volume of ethyl acetate of the mycelium to the residue, sonicate it for 40-60 minutes, collect the extract and repeat the above steps to obtain three extracts, combine and concentrate them to obtain a crude extract; 3) Dissolve the crude extract in chloroform or dichloromethane, and then 18 Mix the sample, dry-load the column, and gradient elute with a methanol:water volume ratio of 1:9-9:
1. Collect the eluate with a methanol:water volume ratio of 9:1, and concentrate by rotary evaporation to obtain component A; 4) Dissolve component A with 1 volume of chloroform, pass through a 200-300 mesh silica gel column, start gradient elution with a volume ratio of petroleum ether: ethyl acetate of 30:1, collect part of the eluate with a volume ratio of petroleum ether: ethyl acetate of 10:1, and concentrate by rotary evaporation to obtain an extract, pass through a 200-300 mesh silica gel column again, start gradient elution with a volume ratio of petroleum ether: chloroform of 8:1, collect part of the eluate with a volume ratio of petroleum ether: chloroform of 4:1, pass through a 200-300 mesh silica gel column chromatography again, start gradient elution with a volume ratio of petroleum ether: ethyl acetate of 20:1, collect part of the eluate with a volume ratio of petroleum ether: ethyl acetate of 5:1, and rotary evaporation to obtain a white powder A'-Neogammacer-21-en-15α-ol, whose structural formula is shown below: ; In step 1), the composition of the rice culture medium is as follows: 100 g rice, 10 g sawdust, and 120 mL pure water; it is sterilized at 121°C for 20 min before use.
2. according to claim 1 Raffaelea lauricola Method for preparing secondary metabolites, Features: In step 1), the size of the bacterial block is 0.5×0.5 cm, and the inoculation amount is 4 blocks.
3. According to claim 1 Raffaelea lauricola Method for preparing secondary metabolites, Features: In step 2), the power of ultrasound is 400 W and the frequency is 35 KHz.
4. according to claim 1 Raffaelea lauricola Method for preparing secondary metabolites, Features: The reverse phase silica gel C used in step 3) 18 Particle size 40-60 μm, pore size 120 Å.
5. According to claim 1 Raffaelea lauricola Method for preparing secondary metabolites, Features: In step 3), the gradient elution ratio was methanol: water volume ratio of 1:9, 2:8, 3:7, 4:6, 6:4, 7:3, 8:2, 9:
1.
6. According to claim 1 Raffaelea lauricola Method for preparing secondary metabolites, Features: In step 4), the volume ratios of petroleum ether:ethyl acetate in the gradient elution were 30:1, 20:1, 10:1, 7:1, 5:1, and the volume ratios of petroleum ether:chloroform were 8:1, 6:1, 4:1.
